Success Story: Pharmacotherapy Researcher from China Secures EB-1A Approval in Just 11 Days
Client’s Testimonial:
"The approval of my EB-1A is truly a great achievement for us, and I attribute much of this success to your team’s hard work and professional support, especially under the current strict immigration environment."
On August 7th, 2026,we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Scholar in the Field of Pharmacotherapy (Approval Notice).
General Field: Pharmacotherapy
Position at the Time of Case Filing: Postdoctoral Scholar
Country of Origin: China
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: August 7th, 2026
Processing Time: 11 days (Premium Processing Requested)
Case Summary:
Developing safer and more effective treatments requires researchers to determine how medicines behave under different biological and clinical conditions. This challenge has been central to the client’s work in pharmacotherapy. Holding a Ph.D. in pharmacotherapy and translational research, the client has developed expertise in evaluating how therapeutic substances are processed by the body, how treatments may affect one another, and how individual differences can influence treatment outcomes. In the client’s current research position, this expertise is being applied to studies designed to improve the evaluation and development of potential therapies.
A Record of Research Influence
North America Immigration Law Group (Chen Immigration Law Associates) prepared the client’s I-140 EB-1A petition around three regulatory criteria, focusing on judging the work of others, original contributions of major significance, and authorship of scholarly articles. We demonstrated that the client’s accomplishments collectively reflected sustained recognition and meaningful influence within the field.
The client’s academic achievements and recognition were reflected in:
- 27 peer-reviewed journal articles, including 6 first-authored publications
- 11 conference abstracts, 1 preprint, and 1 book chapter
- At least 33 completed peer reviews for scholarly journals
- Hundreds of citations, with the client’s publications cited by researchers across at least 47 countries
- A citation record placing the client among the top 1% of highly cited authors publishing on related topics over an eight-year period
The client’s research also received support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a major U.S. federal health research agency, providing additional objective recognition of the value of the work.
Demonstrating Major Significance
Beyond numerical metrics, we showed how independent researchers had relied on the client’s findings to further studies involving medication safety, treatment effectiveness, differences among patient populations, and improved therapeutic strategies. We also highlighted the unusually strong citation performance of several publications, demonstrating that the client’s research attracted recognition beyond what is typical in the field.
The broader value of the client’s research was also recognized by experts in the field. As one recommender noted:
“...[Client] has advanced the field of pharmacotherapy, offering substantial value to the United States. Notably, his work is valuable for addressing the understanding of drug-drug interactions in the administration of COVID-19 treatments…”
By connecting the client’s scholarly output, international citation influence, peer-review activity, research funding, and independent reliance on the client’s findings, North America Immigration Law Group presented a cohesive record of sustained recognition. Filed with premium processing on July 27th, 2026, the petition was approved on August 7th, just 11 days later. We congratulate the client on this achievement and wish the client continued success in advancing safer and more effective therapeutic approaches.